Favorable Press Coverage Somewhat Unlikely to Affect AveXis (AVXS) Stock Price

News articles about AveXis (NASDAQ:AVXS) have been trending positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AveXis earned a news sentiment score of 0.28 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.1095682481206 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

A number of brokerages have issued reports on AVXS. BMO Capital Markets reiterated an “outperform” rating and issued a $130.00 price target (up from $123.00) on shares of AveXis in a report on Thursday. Jefferies Group LLC boosted their target price on shares of AveXis to $118.00 and gave the stock a “buy” rating in a report on Thursday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $130.00 target price on shares of AveXis in a report on Friday, October 6th. UBS AG restated a “buy” rating and issued a $122.00 target price (up from $95.00) on shares of AveXis in a report on Tuesday, October 3rd. Finally, Citigroup Inc. boosted their target price on shares of AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a report on Monday, October 2nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $107.38.

AveXis (NASDAQ AVXS) opened at 104.39 on Monday. The company’s 50 day moving average is $94.94 and its 200-day moving average is $83.81. AveXis has a 1-year low of $43.06 and a 1-year high of $106.00. The stock’s market capitalization is $3.33 billion.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($1.10). During the same period in the previous year, the business posted ($0.68) EPS. Analysts forecast that AveXis will post ($6.22) earnings per share for the current fiscal year.

In related news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $91.52, for a total transaction of $162,905.60. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $162,905.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,340 shares of company stock valued at $2,023,896. 18.60% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/16/favorable-press-coverage-somewhat-unlikely-to-affect-avexis-avxs-stock-price.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply